EOLS - Evolus, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Newport Beach,
United States
Type: Equity
EOLS price evolution
EOLS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $93.67 | $96.96 | $62.84 | |
| Short term investments | ||||
| Net receivables | $44.64 | $43.15 | $34.24 | $30.53 |
| Inventory | $14.89 | $13.38 | $11.55 | $11 |
| Total current assets | $150.36 | $158.13 | $150.26 | $112.42 |
| Long term investments | ||||
| Property, plant & equipment | $10.59 | $7.75 | $7.7 | $7.85 |
| Goodwill & intangible assets | $67.48 | $67.8 | $68.32 | |
| Total noncurrent assets | $75.64 | $75.91 | $76.58 | |
| Total investments | ||||
| Total assets | $229.61 | $233.77 | $226.18 | $189 |
| Current liabilities | ||||
| Accounts payable | $13.84 | $10.28 | $11.22 | $4.27 |
| Deferred revenue | ||||
| Short long term debt | $1.04 | $1.15 | $1.38 | |
| Total current liabilities | $60.81 | $54.12 | $46.8 | $48.29 |
| Long term debt | $121.21 | $125.71 | $125.5 | $125.17 |
| Total noncurrent liabilities | $160.34 | $160.93 | $161.4 | |
| Total debt | $126.75 | $126.65 | $126.55 | |
| Total liabilities | $223.72 | $214.46 | $207.73 | $209.69 |
| Shareholders' equity | ||||
| Retained earnings | -$602.61 | -$583.44 | -$572.09 | -$558.98 |
| Other shareholder equity | -$0.69 | -$0.6 | -$0.56 | -$0.43 |
| Total shareholder equity | $19.31 | $18.44 | -$20.69 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.84 | $53.92 | $146.26 | $102.56 |
| Short term investments | $5 | |||
| Net receivables | $30.53 | $22.45 | $14.66 | $9.68 |
| Inventory | $11 | $18.85 | $1.76 | $3.35 |
| Total current assets | $112.42 | $100.8 | $178.8 | $127.61 |
| Long term investments | ||||
| Property, plant & equipment | $7.85 | $4.56 | $4.09 | $4.71 |
| Goodwill & intangible assets | $68.32 | $69.81 | $71.83 | $76.5 |
| Total noncurrent assets | $76.58 | $77.18 | $78.68 | $81.46 |
| Total investments | $5 | |||
| Total assets | $189 | $177.98 | $257.48 | $209.07 |
| Current liabilities | ||||
| Accounts payable | $4.27 | $8.94 | $6.09 | $9.62 |
| Deferred revenue | ||||
| Short long term debt | $1.38 | $1.32 | $1.26 | $94.66 |
| Total current liabilities | $48.29 | $46.51 | $57.66 | $180.25 |
| Long term debt | $125.17 | $71.88 | $73.48 | $43.65 |
| Total noncurrent liabilities | $161.4 | $112.97 | $117.94 | $101.78 |
| Total debt | $126.55 | $74.42 | $74.74 | $138.32 |
| Total liabilities | $209.69 | $159.48 | $175.61 | $282.03 |
| Shareholders' equity | ||||
| Retained earnings | -$558.98 | -$497.29 | -$422.88 | -$376.07 |
| Other shareholder equity | -$0.43 | -$0.34 | ||
| Total shareholder equity | -$20.69 | $18.5 | $81.88 | -$72.96 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $66.91 | $59.33 | $61 | |
| Cost of revenue | $19.08 | $18.07 | $19.27 | |
| Gross Profit | $47.83 | $41.27 | $41.73 | |
| Operating activities | ||||
| Research & development | $2.35 | $2.08 | $2.38 | |
| Selling, general & administrative | $50.15 | $45.12 | $43.06 | |
| Total operating expenses | $55.53 | $50.19 | $50.36 | |
| Operating income | -$7.7 | -$8.92 | -$8.63 | |
| Income from continuing operations | ||||
| EBIT | -$6.61 | -$8.36 | -$7.65 | |
| Income tax expense | $0.04 | $0.05 | $0.11 | |
| Interest expense | $4.7 | $4.7 | $4.08 | |
| Net income | ||||
| Net income | -$11.35 | -$13.11 | -$11.83 | |
| Income (for common shares) | -$11.35 | -$13.11 | -$11.83 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $202.09 | $148.62 | $99.67 | $56.54 |
| Cost of revenue | $61.56 | $55.89 | $43.53 | $18.3 |
| Gross Profit | $140.53 | $92.73 | $56.14 | $38.24 |
| Operating activities | ||||
| Research & development | $6.56 | $4.74 | $2.06 | $1.72 |
| Selling, general & administrative | $164.94 | $141.84 | $112.07 | $98.19 |
| Total operating expenses | $189.76 | $158.06 | $100.54 | $191.31 |
| Operating income | -$49.23 | -$65.33 | -$44.41 | -$153.07 |
| Income from continuing operations | ||||
| EBIT | -$47.68 | -$65.22 | -$45.37 | -$152.43 |
| Income tax expense | $0.18 | $0.1 | $0.04 | $0.08 |
| Interest expense | $13.83 | $9.1 | $1.4 | $10.5 |
| Net income | ||||
| Net income | -$61.69 | -$74.41 | -$46.81 | -$163.01 |
| Income (for common shares) | -$61.69 | -$74.41 | -$46.81 | -$163.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$11.35 | -$13.11 | -$11.83 | |
| Operating activities | ||||
| Depreciation | $1.58 | $1.56 | $1.52 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.78 | $5.08 | $4.4 | |
| Total cash flows from operations | -$6.47 | -$10.62 | $0.81 | |
| Investing activities | ||||
| Capital expenditures | -$1.25 | -$0.8 | -$0.36 | |
| Investments | ||||
| Total cash flows from investing | -$3.46 | -$1.25 | -$0.8 | -$0.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.51 | $47.49 | $0.03 | |
| Net borrowings | $24.99 | |||
| Total cash flows from financing | $48.73 | $4.48 | $45.66 | $23.52 |
| Effect of exchange rate | -$0.26 | -$0.04 | -$0.13 | $0.18 |
| Change in cash and equivalents | $22.2 | -$3.29 | $34.12 | $24.15 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$61.69 | -$74.41 | -$46.81 | -$163.01 |
| Operating activities | ||||
| Depreciation | $5.87 | $4.5 | $6.31 | $7.68 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16.46 | $10.83 | $9.58 | $10.58 |
| Total cash flows from operations | -$34.01 | -$84.91 | -$33.39 | -$57.87 |
| Investing activities | ||||
| Capital expenditures | -$1.63 | -$2.94 | -$0.97 | -$3.14 |
| Investments | $5 | $15.33 | ||
| Total cash flows from investing | -$1.63 | -$2.94 | $4.03 | $12.19 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.22 | $0.54 | $103.99 | |
| Net borrowings | $49.95 | -$0.5 | -$27.63 | $39.48 |
| Total cash flows from financing | $44.64 | -$4.15 | $73.05 | $38.35 |
| Effect of exchange rate | -$0.09 | -$0.34 | ||
| Change in cash and equivalents | $8.92 | -$92.33 | $43.69 | -$7.33 |
News
Fundamentals
| Market cap | $328.91M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 63.25M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -10.14 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.47 |
| Quick ratio | 2.23 |